<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04246684</url>
  </required_header>
  <id_info>
    <org_study_id>ACO/ARO/AIO-18.1</org_study_id>
    <nct_id>NCT04246684</nct_id>
  </id_info>
  <brief_title>Preoperative Oxaliplatin-based Chemoradiotherapy and Consolidation Chemotherapy Versus Fluorouracil-based Chemoradiotherapy for MRI-defined Intermediate and High-risk Rectal Cancer Patients</brief_title>
  <official_title>Preoperative Oxaliplatin-based Chemoradiotherapy and Consolidation Chemotherapy Versus Fluorouracil-based Chemoradiotherapy for MRI-defined Intermediate and High-risk Rectal Cancer Patients</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Prof. Dr. med. Claus RÃ¶del</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Goethe University</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Preoperative 5-FU-based chemoradiotherapy (CRT) and total mesorectal excision (TME) surgery 6
      weeks thereafter with optional adjuvant chemotherapy is at present a standard of care for
      patients with UICC II and III rectal cancer and used as control arm. With this, pathological
      complete response rates (pCR) are in the range of 10%, 3 year-local failure rates in the
      range of 5%, distant recurrences occur in 25-30% of patients, and 3 years disease-free
      survival (DFS) amounts to 70%. The hereby proposed ACO/ARO/AIO-18.1 randomized trial aims to
      improve standard treatment by incorporating several novel and innovative aspects, partly
      established by our preceding CAO/ARO/AIO-04 and CAO/ARO/AIO-12 randomized trials:

        1. patient selection is based on strict MRI features of intermediate and high-risk
           characteristics

        2. the CRT and chemotherapy(CT) regimens incorporate 5-FU/oxaliplatin with doses and
           intensities shown to be effective and well-tolerated without compromising treatment
           compliance in CAO/ARO/AIO-04

        3. the sequence and interval of CRT, CT, and surgery adopts the innovative total
           neoadjuvant treatment (TNT) approach as established by our CAO/ARO/AIO-12 trial

        4. surgical stratification allows for watch &amp; wait (W&amp;W) management for strictly selected
           patients
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      We hypothesize that the 3-year DFS survival probabilities would improve from 70% in the
      control arm to 78% in the investigational arm (hazard ratio of 0.7). With a power of 90% and
      a two-sided type I error of 5%, the sample size required to obtain a statistically
      significant difference is 822 patients (322 events) in total.
    </textblock>
  </detailed_description>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">January 27, 2020</start_date>
  <completion_date type="Anticipated">December 30, 2028</completion_date>
  <primary_completion_date type="Anticipated">December 30, 2024</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>Investigator-driven</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Single (Investigator)</masking>
    <masking_description>multicentre, open-labeled, Phase III study</masking_description>
  </study_design_info>
  <primary_outcome>
    <measure>disease-free survival (DFS)</measure>
    <time_frame>the 3 years DFS survival</time_frame>
    <description>this is defined as the time from randomisation to one of the following events: no resection of primary tumor due to progression, nonradical surgery of the primary tumor (R2 resection), locoregional recurrence after R0/1 resection of the primary tumor, nonsalvageable local regrowth in case of W&amp;W management (no salvage operation or R2 resection), metastatic disease before, at, or after surgery or W&amp;W management, second primary colorectal or other cancer, or death (all cause), whichever occurs first.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Acute and late toxicity, Incidence of Treatment-Emergent Adverse Events assessment according to NCICTCAE V.5.0</measure>
    <time_frame>3 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Surgical morbidity and complications</measure>
    <time_frame>3 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Rate of sphincter-sparing surgery</measure>
    <time_frame>3 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pathological TNM-staging, Number of participants with histologically complete response</measure>
    <time_frame>3 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>R0 resection rate; negative circumferential resection rate</measure>
    <time_frame>3 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Tumor regression grading according to Dworak</measure>
    <time_frame>3 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Quality of TME according to MERCURY</measure>
    <time_frame>3 years</time_frame>
    <description>Pathological tumor evaluations</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Rate of W&amp;W with or without local regrowth</measure>
    <time_frame>3 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cumulative incidence of local and distant recurrences</measure>
    <time_frame>3 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall survival</measure>
    <time_frame>3 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Quality of life arm and surgical procedures</measure>
    <time_frame>3 years</time_frame>
    <description>QLQ C30, CR29</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Translational study with FACS analyses</measure>
    <time_frame>3 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>functional outcome based on Treatment, Wexner-Vaizey-Score</measure>
    <time_frame>3 years</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">80</enrollment>
  <condition>Rectal Cancer Stage III</condition>
  <arm_group>
    <arm_group_label>Control arm</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>In the control arm patients receive standard preoperative CRT with continuous infusion fluorouracil or oral capecitabine during RT (50.4 Gy in 1.8 Gy fractions), followed by surgical resection 6-10 weeks thereafter. According to the current German S3-guidelines, adjuvant chemotherapy is optional (recommendations are given in the study protocol, but are not mandatory).</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Experimental arm</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>The experimental arm B starts with 5-FU/Oxaliplatin-based CRT, during RT(50.4 Gy in 1.8 Gy fractions), followed by 3 cycles consolidation chemotherapy (mFOLFOX6), and surgery scheduled on day 123.and surgery scheduled on day 123. In both arms, for patients achieving a clinical complete response (cCR), as strictly assessed by clinical investigation, endoscopy and MRI, a watch-and-wait option (W&amp;W) with close follow-up is allowed, if the patient refuses radical surgery or prefers the W&amp;W option.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Oxaliplatin</intervention_name>
    <description>50 mg/m2, iv, day 1, 8, 22, and 29 of radiotherapy</description>
    <arm_group_label>Experimental arm</arm_group_label>
    <other_name>Oxaliplatin 50 mg/m2</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>5FU, 225 mg/m2</intervention_name>
    <description>225 mg/m2 per day, continuous infusion, on day 1-38 of RT</description>
    <arm_group_label>Control arm</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>5FU, 250 mg/m2</intervention_name>
    <description>250 mg/m2 per day, civ, on day 1-14, day 22-35 of radiotherapy</description>
    <arm_group_label>Experimental arm</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>5FU, 2400 mg/m2</intervention_name>
    <description>2400 mg/m2, 46h-civ</description>
    <arm_group_label>Experimental arm</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Oxaliplatin 100 mg/m2</intervention_name>
    <description>100 mg/m2, 2h-civ</description>
    <arm_group_label>Experimental arm</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Folinic Acid</intervention_name>
    <description>400 mg/m2, 2h-civ</description>
    <arm_group_label>Experimental arm</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Radiation</intervention_type>
    <intervention_name>Radiotherapy</intervention_name>
    <description>28 x 1.8 Gy (total: 50.4 Gy), 5 fractions per week</description>
    <arm_group_label>Control arm</arm_group_label>
    <arm_group_label>Experimental arm</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Capecitabine</intervention_name>
    <description>825 mg/m2 bid, per os, on day 1-38 of RT</description>
    <arm_group_label>Control arm</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  diagnosis of rectal adenocarcinoma localised 0 - 12 cm from the anocutaneous line as
             measured by rigid rectoscopy (i.e. lower and middle third of the rectum)

          -  Staging requirements: High-resolution, thin-sliced (i.e. 3mm) magnetic resonance
             imaging (MRI) of the pelvis is the mandatory local staging procedure.

          -  MRI-defined inclusion criteria: presence of at least one of the following high-risk
             conditions:

          -  any cT3 if the distal extent of the tumor is &lt; 6 cm from the anocutaneous line, or

          -  cT3c/d in the middle third of the rectum (â¥ 6-12 cm) with MRI evidence of extramural
             tumor spread into the mesorectal fat of more than 5 mm (&gt;cT3b), or

          -  cT3 with clear cN+ based on strict MRI-criteria

          -  cT4 tumors, or

          -  mrCRM+ (&lt; 1mm), or

          -  Extramural venous invasion (EMVI+)

          -  Trans-rectal endoscopic ultrasound (EUS) is additionally used when MRI is not
             definitive to exclude early cT1/T2 disease in the lower third of the rectum or early
             cT3a/b tumors in the middle third of the rectum.

          -  Spiral-CT of the abdomen and chest to exclude distant metastases.

          -  Aged at least 18 years. No upper age limit.

          -  WHO/ECOG Performance Status 0-1

        Exclusion Criteria:

          -  Lower border of the tumor localised more than 12 cm from the anocutaneous line as
             measured by rigid rectoscopy

          -  Distant metastases (to be excluded by CT scan of the thorax and abdomen)

          -  Prior antineoplastic therapy for rectal cancer

          -  Prior radiotherapy of the pelvic region

          -  Major surgery within the last 4 weeks prior to inclusion

          -  Subject pregnant or breast feeding, or planning to become pregnant within 6 months
             after the end of treatment.

          -  Subject (male or female) is not willing to use highly effective methods of
             Contraception during treatment and for 6 months after the end of treatment.

          -  On-treatment participation in a clinical study in the period 30 days prior to
             inclusion

          -  Previous or current drug abuse

          -  Other concomitant antineoplastic therapy

          -  Serious concurrent diseases, including neurologic or psychiatric disorders (incl.
             dementia and uncontrolled seizures), active, uncontrolled infections, active,
             disseminated coagulation disorder

          -  Clinically significant cardiovascular disease in (incl. myocardial infarction,
             unstable angina, symptomatic congestive heart failure, serious uncontrolled cardiac
             arrhythmia) &lt; 6 months before enrolment

          -  Prior or concurrent malignancy &lt; 3 years prior to enrolment in study (Exception:
             non-melanoma Skin cancer or cervical carcinoma FIGO stage 0-1), if the patient is
             continuously disease-free

          -  Known allergic reactions on study medication

          -  Known dihydropyrimidine dehydrogenase deficiency

          -  Psychological, familial, sociological or geographical condition potentially hampering
             compliance with the study protocol and follow-up schedule (these conditions should be
             discussed with the patient before registration in the trial).
      </textblock>
    </criteria>
    <gender>All</gender>
    <gender_based>Yes</gender_based>
    <gender_description>Male and female patients with histologically confirmed diagnosis of rectal adenocarcinoma localised 0 - 12 cm from the anocutaneous line as measured by rigid rectoscopy</gender_description>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Claus Roedel, Prof. Dr.</last_name>
    <phone>0049-69-6301</phone>
    <phone_ext>5130</phone_ext>
    <email>claus.roedel@kgu.de</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Emmanouil Fokas, Prof. Dr.</last_name>
    <phone>0049-69-6301</phone>
    <phone_ext>5130</phone_ext>
    <email>emmanouil.fokas@kgu.de</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Clincal Center Esslingen</name>
      <address>
        <city>Esslingen</city>
        <state>Baden-Wuerttemberg</state>
        <zip>73730</zip>
        <country>Germany</country>
      </address>
    </facility>
    <contact>
      <last_name>Ludger Staib, Prof. Dr.</last_name>
      <phone>0711-3103-82600</phone>
      <email>l.staib@klinikum-esslingen.de</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>University Clinic Freiburg</name>
      <address>
        <city>Freiburg</city>
        <state>Baden-Wuerttemberg</state>
        <zip>79106</zip>
        <country>Germany</country>
      </address>
    </facility>
    <contact>
      <last_name>Simon Kirste, Dr. med.</last_name>
      <phone>0761-270-94610</phone>
      <email>simon.kirste@uniklinik-freiburg.de</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>University Clinic Mannheim</name>
      <address>
        <city>Mannheim</city>
        <state>Baden-Wuerttemberg</state>
        <zip>68167</zip>
        <country>Germany</country>
      </address>
    </facility>
    <contact>
      <last_name>Ralf-Dieter Hofheinz, Prof.Dr.med.</last_name>
      <phone>0621-383 28 55</phone>
      <email>ralf.hofheinz@umm.de</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Medius Clincal Center Ostfildern-Ruit</name>
      <address>
        <city>Ostfildern</city>
        <state>Baden-Wuerttemberg</state>
        <zip>73760</zip>
        <country>Germany</country>
      </address>
    </facility>
    <contact>
      <last_name>Matthias Geiger, Dr. med.</last_name>
      <phone>0711-4488-11660</phone>
      <email>m.geiger@medius.kliniken.de</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>University Clinic for Radioncology TÃ¼bingen</name>
      <address>
        <city>TÃ¼bingen</city>
        <state>Baden-Wuerttemberg</state>
        <zip>72076</zip>
        <country>Germany</country>
      </address>
    </facility>
    <contact>
      <last_name>Cihan Gani, Dr. med.</last_name>
      <phone>07071-2968338</phone>
      <email>cihan.gani@med.uni-tuebingen.de</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Clincal Center &quot;St. Marien&quot; Amberg</name>
      <address>
        <city>Amberg</city>
        <state>Bavaria</state>
        <zip>92224</zip>
        <country>Germany</country>
      </address>
    </facility>
    <contact>
      <last_name>Ludwig Fischer von Weikersthal, Dr. med.</last_name>
      <phone>9621-38-1637</phone>
      <email>Weikersthal.ludwig@klinikum-amberg.de</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Clinical Center Coburg</name>
      <address>
        <city>Coburg</city>
        <state>Bavaria</state>
        <zip>96450</zip>
        <country>Germany</country>
      </address>
    </facility>
    <contact>
      <last_name>Gerhard Grabenbauer, Prof. Dr.</last_name>
      <phone>09561-249125</phone>
      <email>gg@diestrahlentherapeuten.de</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>University Clinic Erlangen</name>
      <address>
        <city>Erlangen</city>
        <state>Bavaria</state>
        <zip>91054</zip>
        <country>Germany</country>
      </address>
    </facility>
    <contact>
      <last_name>Rainer Fietkau, Prof. Dr.</last_name>
      <phone>09131-85-33405</phone>
      <email>rainer.fietkau@uk-erlangen.de</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Technical University Munich</name>
      <address>
        <city>MÃ¼nchen</city>
        <state>Bavaria</state>
        <zip>81675</zip>
        <country>Germany</country>
      </address>
    </facility>
    <contact>
      <last_name>Daniel Reim, PD Dr. med.</last_name>
      <phone>089-41405019</phone>
      <email>Daniel.reim@tum.de</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Clincal Center &quot;Bogenhausen&quot; Munich</name>
      <address>
        <city>MÃ¼nchen</city>
        <state>Bavaria</state>
        <zip>81925</zip>
        <country>Germany</country>
      </address>
    </facility>
    <contact>
      <last_name>Martin Fuchs, Dr. med.</last_name>
      <phone>089-9270-2462</phone>
      <email>Martin.fuchs@muenchen-klinik.de</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Hospital &quot;Barmherzige BrÃ¼der&quot; Regensburg</name>
      <address>
        <city>Regensburg</city>
        <state>Bavaria</state>
        <zip>93046</zip>
        <country>Germany</country>
      </address>
    </facility>
    <contact>
      <last_name>Anke Schlenska-Lange, Dr. med.</last_name>
      <phone>0941-369-2151</phone>
      <email>anke.schlenska-lange@barmherzige-regensburg.de</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>University Clinic Regensburg</name>
      <address>
        <city>Regensburg</city>
        <state>Bavaria</state>
        <zip>93053</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University Clinic WÃ¼rzburg</name>
      <address>
        <city>WÃ¼rzburg</city>
        <state>Bavaria</state>
        <zip>97080</zip>
        <country>Germany</country>
      </address>
    </facility>
    <contact>
      <last_name>BÃ¼lent Polat, PD Dr. med.</last_name>
      <phone>0931-201-28918</phone>
      <email>polat_b@klinik.uni-wuerzburg.de</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Clincal Center Helios Bad Saarrow</name>
      <address>
        <city>Bad Saarow</city>
        <state>Brandenburg</state>
        <zip>15526</zip>
        <country>Germany</country>
      </address>
    </facility>
    <contact>
      <last_name>Daniel Pink, PD Dr. med.</last_name>
      <phone>033631-73527</phone>
      <email>daniel.pink@helios-gesundheit.de</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Clincal Center Darmstadt</name>
      <address>
        <city>Darmstadt</city>
        <state>Hessen</state>
        <zip>64283</zip>
        <country>Germany</country>
      </address>
    </facility>
    <contact>
      <last_name>Christian WeiÃ, Prof.Dr.med.</last_name>
      <phone>06151-1076851</phone>
      <email>christan.weiss@mail.klinikum-darmstadt.de</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>DRK Clincal Centers North Hessen Kassel</name>
      <address>
        <city>Kassel</city>
        <state>Hessen</state>
        <zip>34121</zip>
        <country>Germany</country>
      </address>
    </facility>
    <contact>
      <last_name>Mathias KleiÃ, Dr. med.</last_name>
      <phone>0561-3086-74100</phone>
      <email>kleiss@drk-nh.de</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>University Clinic Marburg</name>
      <address>
        <city>Marburg</city>
        <state>Hessen</state>
        <zip>35043</zip>
        <country>Germany</country>
      </address>
    </facility>
    <contact>
      <last_name>Rita Engenhart-Cabillic, Prof.Dr.med.</last_name>
      <phone>06421-5866-434</phone>
      <email>Rita.Engenhart-Cabillic@uk-gm.de</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Sana Clinical Center Offenbach</name>
      <address>
        <city>Offenbach</city>
        <state>Hessen</state>
        <zip>63069</zip>
        <country>Germany</country>
      </address>
    </facility>
    <contact>
      <last_name>Silla Hey-Koch, Dr. med.</last_name>
      <phone>069-8405-7491</phone>
      <email>silla.hey-koch@sana.de</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Lahn-Dill Clinics Wetzlar</name>
      <address>
        <city>Wetzlar</city>
        <state>Hessen</state>
        <zip>35578</zip>
        <country>Germany</country>
      </address>
    </facility>
    <contact>
      <last_name>Wolfram Wannack</last_name>
      <phone>06441-7922380</phone>
      <email>wolfram.wannack@lahn-dill-kliniken.de</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Oncology Practice Celle</name>
      <address>
        <city>Celle</city>
        <state>Lower Saxony</state>
        <zip>29221</zip>
        <country>Germany</country>
      </address>
    </facility>
    <contact>
      <last_name>Michael Varvenne, Dr. med.</last_name>
      <phone>05141-97474-0</phone>
      <email>Michael.Varvenne@onkologie.de</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>University Clinic GÃ¶ttingen</name>
      <address>
        <city>GÃ¶ttingen</city>
        <state>Lower Saxony</state>
        <zip>37075</zip>
        <country>Germany</country>
      </address>
    </facility>
    <contact>
      <last_name>Lena-Christin Conradi, Dr. Dr. med.</last_name>
      <phone>0551-39-8323</phone>
      <email>lena.conradi@med.uni-goettingen.de</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Medical Project Hannover</name>
      <address>
        <city>Hannover</city>
        <state>Lower Saxony</state>
        <zip>30171</zip>
        <country>Germany</country>
      </address>
    </facility>
    <contact>
      <last_name>Michael Koenigsmann, Prof.Dr.med.</last_name>
      <phone>0511-89979680</phone>
      <email>koenigsmann@onkologie-hannover.de</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>&quot;St. Bernward&quot; Clincal Center Hildesheim</name>
      <address>
        <city>Hildesheim</city>
        <state>Lower Saxony</state>
        <zip>31134</zip>
        <country>Germany</country>
      </address>
    </facility>
    <contact>
      <last_name>Ulrich Kaiser, Prof.Dr.med.</last_name>
      <phone>05121-901274</phone>
      <email>prof.dr.u.kaiser@bernward-khs.de</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Oncology in Medicinum Hildesheim</name>
      <address>
        <city>Hildesheim</city>
        <state>Lower Saxony</state>
        <zip>31135</zip>
        <country>Germany</country>
      </address>
    </facility>
    <contact>
      <last_name>Werner Freier, Dr. med.</last_name>
      <phone>051-2191-291421</phone>
      <email>Study-nurse@onkologie-hildesheim.de</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>University Clinic Oldenburg</name>
      <address>
        <city>Oldenburg</city>
        <state>Lower Saxony</state>
        <zip>26133</zip>
        <country>Germany</country>
      </address>
    </facility>
    <contact>
      <last_name>Claus-Henning KÃ¶hne, Prof.Dr.med.</last_name>
      <phone>0441-403-2611</phone>
      <email>onkologie@klinikum-oldenburg.de</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Clincal Center &quot;Dr. Hancken&quot; Stade</name>
      <address>
        <city>Stade</city>
        <state>Lower Saxony</state>
        <zip>21680</zip>
        <country>Germany</country>
      </address>
    </facility>
    <contact>
      <last_name>Johannes Meiler, Dr. med.</last_name>
      <phone>04141-604-232</phone>
      <email>johannes.meiler@hancken.de</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Franziskus Hospital Bielefeld</name>
      <address>
        <city>Bielefeld</city>
        <state>North Rhine-Westphalia</state>
        <zip>33615</zip>
        <country>Germany</country>
      </address>
    </facility>
    <contact>
      <last_name>JÃ¶rg Thomas Hartmann, Prof.Dr.med.</last_name>
      <phone>0521-589-1201</phone>
      <email>joerg.Hartmann@franziskus.de</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Hospital Bochum</name>
      <address>
        <city>Bochum</city>
        <state>North Rhine-Westphalia</state>
        <zip>44892</zip>
        <country>Germany</country>
      </address>
    </facility>
    <contact>
      <last_name>Michael Pohl, Dr. med.</last_name>
      <phone>0234-299-80400</phone>
      <email>michael.a.pohl@web.de</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>University Clinic Essen</name>
      <address>
        <city>Essen</city>
        <state>North Rhine-Westphalia</state>
        <zip>45122</zip>
        <country>Germany</country>
      </address>
    </facility>
    <contact>
      <last_name>Thomas Gauler, Dr. med.</last_name>
      <phone>0201-723-85057</phone>
      <email>Thomas.gauler@uk-essen.de</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Clinical Center &quot;Essen Mitte&quot;</name>
      <address>
        <city>Essen</city>
        <state>North Rhine-Westphalia</state>
        <zip>45136</zip>
        <country>Germany</country>
      </address>
    </facility>
    <contact>
      <last_name>Christian MÃ¼ller, Dr. med.</last_name>
      <phone>020-1174-24003</phone>
      <email>ch.mueller@kem-med.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>MVZ Center for Oncology &amp; Haematology Cologne</name>
      <address>
        <city>KÃ¶ln</city>
        <state>North Rhine-Westphalia</state>
        <zip>50677</zip>
        <country>Germany</country>
      </address>
    </facility>
    <contact>
      <last_name>Kai Severin, Dr. med.</last_name>
      <phone>0221-9318220</phone>
      <email>severin-studien@oncokoeln.de</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>St. Vincenz Hospital Paderborn</name>
      <address>
        <city>Paderborn</city>
        <state>North Rhine-Westphalia</state>
        <zip>33098</zip>
        <country>Germany</country>
      </address>
    </facility>
    <contact>
      <last_name>Jobst Greeve, Prof.Dr.med.</last_name>
      <phone>05251-86-1101</phone>
      <email>j.greeve@vincenz.de</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Prosper Hospital Recklinghausen</name>
      <address>
        <city>Recklinghausen</city>
        <state>North Rhine-Westphalia</state>
        <zip>45659</zip>
        <country>Germany</country>
      </address>
    </facility>
    <contact>
      <last_name>Thomas HÃ¶hler, Prof. Dr.</last_name>
      <phone>02361-54-2650</phone>
      <email>thomas.hoehler@prosper-hospital.de</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>St. Josephs Hospital Warendorf</name>
      <address>
        <city>Warendorf</city>
        <state>North Rhine-Westphalia</state>
        <zip>48231</zip>
        <country>Germany</country>
      </address>
    </facility>
    <contact>
      <last_name>Christoph Michael Seiler, Prof.Dr.med.</last_name>
      <phone>02581-20-1301</phone>
      <email>c.seiler@jhwaf.de</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Westpfalz Clinical Center Kaiserslautern</name>
      <address>
        <city>Kaiserslautern</city>
        <state>Rhineland-Palatinate</state>
        <zip>67655</zip>
        <country>Germany</country>
      </address>
    </facility>
    <contact>
      <last_name>Gerhard held, Prof.Dr.med.</last_name>
      <phone>0631-2013-1260</phone>
      <email>gheld@westpfalz-klinikum.de</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Clinical Center &quot;Mutterhaus&quot; Trier</name>
      <address>
        <city>Trier</city>
        <state>Rhineland-Palatinate</state>
        <zip>54290</zip>
        <country>Germany</country>
      </address>
    </facility>
    <contact>
      <last_name>Rolf Mahlberg, Dr. med.</last_name>
      <phone>0651-9472571</phone>
      <email>mahlberg@mutterhaus.de</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Oncology Center Lebach</name>
      <address>
        <city>Lebach</city>
        <state>Saarland</state>
        <zip>66822</zip>
        <country>Germany</country>
      </address>
    </facility>
    <contact>
      <last_name>Stefan Bauer, PD Dr. med.</last_name>
      <phone>06881-501-500</phone>
      <email>stefanbauer@onkologie-lebach.de</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Clincal Center Chemnitz</name>
      <address>
        <city>Chemnitz</city>
        <state>Saxony</state>
        <zip>09113</zip>
        <country>Germany</country>
      </address>
    </facility>
    <contact>
      <last_name>Gunther Klautke, PD Dr. med.</last_name>
      <phone>0371-333-42538</phone>
      <email>g.klautke@skc.de</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Oncology Center Dresden</name>
      <address>
        <city>Dresden</city>
        <state>Saxony</state>
        <zip>01127</zip>
        <country>Germany</country>
      </address>
    </facility>
    <contact>
      <last_name>Thomas GÃ¶hler, Dr. med.</last_name>
      <phone>0351-795-2550</phone>
      <email>goehler@onkozentrum.de</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Oncology Practice Dresden</name>
      <address>
        <city>Dresden</city>
        <state>Saxony</state>
        <zip>01307</zip>
        <country>Germany</country>
      </address>
    </facility>
    <contact>
      <last_name>Lutz Jacobasch, Dr. med.</last_name>
      <phone>0351-4400228</phone>
      <email>jacobasch@onkologie-dresden.net</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>University Clinic Leipzig</name>
      <address>
        <city>Leipzig</city>
        <state>Saxony</state>
        <zip>04103</zip>
        <country>Germany</country>
      </address>
    </facility>
    <contact>
      <last_name>Thomas Kuhnt, Prof. Dr.</last_name>
      <phone>0341-9718400</phone>
      <email>thomas.kuhnt@medizin.uni-leipzig.de</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Vivantes Clincial Center in Friedrichshain</name>
      <address>
        <city>Berlin</city>
        <zip>10249</zip>
        <country>Germany</country>
      </address>
    </facility>
    <contact>
      <last_name>Andreas W. Berger, PD Dr. med.</last_name>
      <phone>030-1302-32481</phone>
      <email>Andreas.berger@vivantes.de</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Clincal Center Helios Berlin Buch</name>
      <address>
        <city>Berlin</city>
        <zip>13125</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Department of Radiooncology</name>
      <address>
        <city>Frankfurt</city>
        <zip>60590</zip>
        <country>Germany</country>
      </address>
    </facility>
    <contact>
      <last_name>Claus Roedel, Prof. Dr.</last_name>
      <phone>0049-69-6301</phone>
      <phone_ext>5130</phone_ext>
      <email>claus.roedel@kgu.de</email>
    </contact>
    <contact_backup>
      <last_name>Emmanouil Fokas, Prof. Dr. Dr.</last_name>
      <phone>0049-69-6301</phone>
      <phone_ext>5130</phone_ext>
      <email>emmanouil.fokas@kgu.de</email>
    </contact_backup>
  </location>
  <location_countries>
    <country>Germany</country>
  </location_countries>
  <verification_date>January 2020</verification_date>
  <study_first_submitted>January 23, 2020</study_first_submitted>
  <study_first_submitted_qc>January 28, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">January 29, 2020</study_first_posted>
  <last_update_submitted>January 30, 2020</last_update_submitted>
  <last_update_submitted_qc>January 30, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">February 5, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>Goethe University</investigator_affiliation>
    <investigator_full_name>Prof. Dr. med. Claus RÃ¶del</investigator_full_name>
    <investigator_title>Prof. Dr. med.</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Rectal Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Leucovorin</mesh_term>
    <mesh_term>Folic Acid</mesh_term>
    <mesh_term>Capecitabine</mesh_term>
    <mesh_term>Fluorouracil</mesh_term>
    <mesh_term>Oxaliplatin</mesh_term>
    <mesh_term>Levoleucovorin</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

